Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2/3 signaling, is now FDA approved for the treatment of very low to intermediate risk MDS with ring sideroblasts and SF3B1 mutation. Here, SF3B1 is linked to myelodysplastic syndrome.